Collect 1 mL (Min: 0.8 mL, Max 1.2 mL) of whole blood directly into each of the four tubes in the QuantiFERON-TB (High Altitude) 4 In-Tube Collection Kit. Note: Tubes should be between 17°C and 25°C (63°F to 77°F) at the time of blood collection.
Tubes have low vacuum and fill extremely slow.
To avoid underfilling tubes: it may be helpful to collect patients’ blood sample using a syringe. With the full syringe inoculate the 4 tubes to their fill lines. Do not allow blood to sit in syringe, fill 4 tubes immediately.
Immediately after filling the tubes, shake them ten (10) times just firmly enough to ensure the entire inner surface of the tube is coated with blood, to solubilize antigens on the tube walls. Note: Over-energetic shaking may cause gel disruption and could lead to aberrant results.
Attach label to the appropriate tube color as follows:
Gray tube with accession number ending in .1 (GRY)
Green tube with accession number ending in .2 (GRN)
Yellow tube with accession number ending in .3 (YEL)
Purple tube with accession number ending in .4 (PUR)
Specimen Preparation
Specimens may remain ambient for up to 16 hours after collection before being placed in an incubator.
After mixing, and within 16 hours of collection, incubate upright at 37°C for 16 - 24 hours.
After incubation, centrifuge for 15 minutes at 2000 - 3000 RCF (g).
After centrifugation, transport entire contents in each of the 4 original collection tubes.
Unacceptable Conditions
Specimens refrigerated prior to incubation are not acceptable for testing.
Sample not properly identified
Incorrect container
Insufficient sample volume
If volume of blood collected is above or below the black bar indicated in photo, the sample is unacceptable.
Storage/Transport Temperature
Specimens must remain at room temperature between collection and incubation. Specimens refrigerated prior to incubation are not acceptable for testing.
Internal: Deliver to lab immediately. Offsite: Transport ASAP at ambient temperature. (excluding Harmony ED Lab)
Stability (from collection to initiation)
Before incubation or centrifugation: Ambient: 16 hours
After incubation and centrifugation: Ambient: 2 hours
Refrigerated: 4 weeks
Frozen: Unacceptable
Performed
UCH: Mon-Fri
Performed
UCH: Mon-Fri
Methodology
Lymphocytes Stimulation and Chemiluminescence immunoassay (CLIA)
Assay is FDA-approved for in vitro diagnostic use.
Reported
2-4 days
Synonyms
Interferon-Gamma Release Assay for Tuberculosis
Latent Tuberculosis Infection (LTBI)
QFT & M TB
QFT-G & M. tuberculosis
QFT-TB
Quantiferon Mitogen and NIL
QuantiFERON-TB Gold In Tube & Mycobacterium tuberculosis Antibody
Ordering Recommendations
Aid in the detection of latent disease among persons at increased risk for tuberculosis (TB). Positive predictive value is less in low-risk populations. May be used in persons who have received BCG vaccine.
Epic ID
LAB8965
Reference Interval
Negative
Interpretive Data
A negative result must be correlated with the individual’s medical and historical data, particularly for individuals with impaired immune function:
Collect 1 mL (Min: 0.8 mL, Max 1.2 mL) of whole blood directly into each of the four tubes in the QuantiFERON-TB (High Altitude) 4 In-Tube Collection Kit. Note: Tubes should be between 17°C and 25°C (63°F to 77°F) at the time of blood collection.
Tubes have low vacuum and fill extremely slow.
To avoid underfilling tubes: it may be helpful to collect patients’ blood sample using a syringe. With the full syringe inoculate the 4 tubes to their fill lines. Do not allow blood to sit in syringe, fill 4 tubes immediately.
Immediately after filling the tubes, shake them ten (10) times just firmly enough to ensure the entire inner surface of the tube is coated with blood, to solubilize antigens on the tube walls. Note: Over-energetic shaking may cause gel disruption and could lead to aberrant results.
Attach label to the appropriate tube color as follows:
Gray tube with accession number ending in .1 (GRY)
Green tube with accession number ending in .2 (GRN)
Yellow tube with accession number ending in .3 (YEL)
Purple tube with accession number ending in .4 (PUR)
Specimen Preparation
Specimens may remain ambient for up to 16 hours after collection before being placed in an incubator.
After mixing, and within 16 hours of collection, incubate upright at 37°C for 16 - 24 hours.
After incubation, centrifuge for 15 minutes at 2000 - 3000 RCF (g).
After centrifugation, transport entire contents in each of the 4 original collection tubes.
Unacceptable Conditions
Specimens refrigerated prior to incubation are not acceptable for testing.
Sample not properly identified
Incorrect container
Insufficient sample volume
If volume of blood collected is above or below the black bar indicated in photo, the sample is unacceptable.
Storage/Transport Temperature
Specimens must remain at room temperature between collection and incubation. Specimens refrigerated prior to incubation are not acceptable for testing.
Internal: Deliver to lab immediately. Offsite: Transport ASAP at ambient temperature. (excluding Harmony ED Lab)
Stability (from collection to initiation)
Before incubation or centrifugation: Ambient: 16 hours
After incubation and centrifugation: Ambient: 2 hours
Refrigerated: 4 weeks
Frozen: Unacceptable
Performed
UCH: Mon-Fri
Ordering
Performed
UCH: Mon-Fri
Methodology
Lymphocytes Stimulation and Chemiluminescence immunoassay (CLIA)
Assay is FDA-approved for in vitro diagnostic use.
Reported
2-4 days
Synonyms
Interferon-Gamma Release Assay for Tuberculosis
Latent Tuberculosis Infection (LTBI)
QFT & M TB
QFT-G & M. tuberculosis
QFT-TB
Quantiferon Mitogen and NIL
QuantiFERON-TB Gold In Tube & Mycobacterium tuberculosis Antibody
Ordering Recommendations
Aid in the detection of latent disease among persons at increased risk for tuberculosis (TB). Positive predictive value is less in low-risk populations. May be used in persons who have received BCG vaccine.
Epic ID
LAB8965
Result Interpretation
Reference Interval
Negative
Interpretive Data
A negative result must be correlated with the individual’s medical and historical data, particularly for individuals with impaired immune function:
